LeituraPesquisaRadarFramework de investimento
Entrar / Cadastrar
← Voltar para a leitura
NotíciasTópico · 直觉外科Material2 min de leituraEditorial DisconfirmAI

Intuitive Surgical Q3 Revenue Up 21.5%, Buybacks Offset Margin Pressure from Strategic Pricing Cuts

Intuitive Surgical reports strong Q3 growth but accepts short-term margin hits via price cuts to defend market share, supported by nearly $3B in share repurchases.

2026-10-22 22:25 GMT+8

US surgical robotics company Intuitive Surgical reported third-quarter results showing 21.5% year-over-year revenue growth to just over $3 billion, beating consensus estimates by more than 400 basis points. Despite robust core performance, the company disclosed two impairments affecting margins: a one-time settlement related to a known class-action lawsuit and strategic pricing adjustments aimed at expanding its addressable market.

Management announced a reduction in per-procedure revenue by 3% to 5%, targeting high-volume procedures to compete against entrants like Medtronic and Johnson & Johnson. This strategy sacrifices some short-term profitability but is expected to be offset by increased procedure volumes, maintaining a healthy cash flow outlook. Adjusted net income rose 21.1% year-over-year, while adjusted EPS grew 25%, accelerated by share buybacks.

In terms of capital allocation, Intuitive Surgical executed nearly $3 billion in aggressive share repurchases during Q3, reducing the average share count by 2.8% compared to last year. The company does not pay dividends, opting for flexible buybacks to return capital. While cash balances declined due to repurchases and higher inventory, the balance sheet remains resilient.

The company narrowed its full-year revenue growth guidance to 14% to 15%, approximately 60 basis points below the midpoint of analyst expectations, but raised its profit forecast. Analysts note that institutional ownership remains stable and price targets are firming, suggesting the market is digesting temporary margin pressure while focusing on long-term market share defense and cash generation capabilities. However, the premium valuation above 40x P/E remains a risk factor if future earnings disappoint.

Entrar / Cadastrar
LeituraPesquisaRadarFramework de investimento

Fontes

  • marketbeat.comMarketBeat↗
Tópico

直觉外科

美国医疗科技公司直觉外科(Intuitive Surgical, ISRG)公布2026年第三季度强劲业绩,营收同比增长21.5%至30.5亿美元,非GAAP每股收益增长25%至3美元。然而,为应对竞争及扩大良性手术采用率,公司宣布将于20…

3 etapas1 peçasAtualizado 2026-11-07 05:12

Como chegamos aqui

  1. 2026-10-20直觉外科发布2026年第三季度财报,营收达30.5亿美元,同比增长21.5%,但GAAP净利润因4.5亿美元反垄断和解金降至5.23亿美元。finance.yahoo.com ↗
  2. 2026-10-21在财报电话会议上,CFO Jamie Samath确认将延长器械使用寿命并引入基于量的定价,预计完全实施后da Vinci器械单次手术收入将下降3%-5%。finance.yahoo.com ↗
  3. 2026-10-22媒体报道指出,尽管Q3表现强劲,但降价换量策略与巨额回购对冲了利润率压力,美国da Vinci手术增长率降至疫情以来最低的10%。marketbeat.com ↗

O que ainda está indefinido

  • 2027年全面实施的降价策略是否真能通过提升手术量(特别是良性手术)来抵消单次收入的下降?
  • 中国自2026年11月起实施的政策性价格下调对国际业务增长的具体影响程度如何?
  • 美国da Vinci手术增长率降至10%是暂时性基数效应还是长期需求疲软的信号?
Ler o tópico completo →
Continuar pesquisando →